The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the th
The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.
대표청구항▼
1. A method for treating a blood vessel, the method comprising: inserting a balloon catheter into the blood vessel, the balloon catheter comprising: an inflatable polyamide balloon; anda coating layer that adheres to an exterior surface of the inflatable polyamide balloon,wherein:the coating layer c
1. A method for treating a blood vessel, the method comprising: inserting a balloon catheter into the blood vessel, the balloon catheter comprising: an inflatable polyamide balloon; anda coating layer that adheres to an exterior surface of the inflatable polyamide balloon,wherein:the coating layer comprises a hydrophobic therapeutic agent and a water-soluble additive;the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;the water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;inflating the balloon catheter to press the coating layer into contact with walls of the blood vessel during a balloon inflation time of 2 minutes or less;releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the walls of the blood vessel during the balloon inflation time;deflating the inflated balloon catheter in the blood vessel at the end of the balloon inflation time; andwithdrawing the deflated balloon catheter from the blood vessel. 2. The method of claim 1, wherein the water-soluble additive is selected from a group consisting of PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate, PEG-20 oleate, PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate, and PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 3. The method of claim 1, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 4. The method of claim 1, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 5. The method of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μg/mm2 to 20 μg/mm2. 6. The method of claim 1, wherein the concentration of the water-soluble additive in the coating layer is from 1 μg/mm2 to 10 μg/mm2. 7. The method of claim 1, wherein the ratio by weight of the water-soluble additive to the therapeutic agent in the coating layer is from about 0.5 to 2. 8. The method of claim 1, wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter. 9. The method of claim 1, wherein the balloon catheter further comprises a dimethylsulfoxide solvent layer overlying the coating layer. 10. The method of claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin. 11. The method of claim 1, wherein the hydrophobic therapeutic agent is paclitaxel. 12. The method of claim 1, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 13. The method of claim 1, wherein the coating layer does not include an iodine covalent bonded contrast agent, oil, or a lipid. 14. The method of claim 1, wherein the coating layer does not include a polymer. 15. The method of claim 1, further comprising: crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the body passage. 16. A method for treating a blood vessel, the method comprising: removing plaque from a target site of the blood vessel;inserting a balloon catheter into the blood vessel to the target site, the balloon catheter comprising: an inflatable polyamide balloon; anda coating layer that adheres to an exterior surface of the inflatable polyamide balloon,wherein:the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;inflating the balloon catheter to press the coating layer into contact with walls of the blood vessel during a balloon inflation time of 2 minutes or less;releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the walls of the blood vessel during the balloon inflation time;deflating the inflated balloon catheter in the blood vessel at the end of the balloon inflation time; andwithdrawing the deflated balloon catheter from the blood vessel. 17. The method of claim 6, wherein removing plaque from the target site of the blood vessel comprises removing the plaque by one of a debulking catheter, a laser atherectomy, a directing atherectomy, or a rotational atherectomy. 18. The method of claim 16, wherein the balloon catheter is inserted into the blood vessel after the plaque is removed. 19. The method of claim 16, further comprising: crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the blood vessel. 20. The method of claim 16, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 21. The method of claim 16, wherein the concentration of the therapeutic agent in the coating layer is from 1 μg/mm2 to 20 μg/mm2. 22. The method of claim 16, wherein the ratio by weight of the water-soluble additive to the therapeutic agent in the coating layer is from about 0.1 to 5. 23. The method of claim 16, wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter. 24. The method of claim 16, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof. 25. The method of claim 16, wherein the hydrophobic therapeutic agent is paclitaxel. 26. The method of claim 16, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 27. The method of claim 16, wherein the coating layer does not include an iodine covalent bonded contrast agent, oil, or a lipid. 28. The method of claim 16, wherein the coating layer does not include a polymer. 29. A method for treating tissue in a body passage of a body, the method comprising: inserting a balloon catheter into the body passage, the balloon catheter comprising: an inflatable polyamide balloon; anda coating layer that adheres to an exterior surface of the inflatable polyamide balloon,wherein:the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;inflating the balloon catheter to contact the coating layer with the tissue in the body passage during a balloon inflation time of 2 minutes or less;releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the tissue in the body passage during the balloon inflation time;deflating the inflated balloon catheter in the body passage at the end of the balloon inflation time; andwithdrawing the deflated balloon catheter from the body passage. 30. The method of claim 29, wherein the tissue is selected from the group consisting of coronary vasculature tissue, peripheral vasculature tissue, cerebral vasculature tissue, esophageal tissue, pulmonary airway tissue, sinus tissue, tracheal tissue, colon tissue, biliary tract tissue, urinary tract tissue, prostate tissue, and brain passage tissue. 31. The method of claim 29, further comprising: crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the body passage. 32. The method of claim 29, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 33. The method of claim 29, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 34. The method of claim 29, further comprising a dimethylsulfoxide solvent layer overlying the coating layer. 35. The method of claim 29, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin. 36. The method of claim 29, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (223)
Caufield Craig E. (Princeton Junction NJ) Grinfeld Alexander A. (Princeton Junction NJ), 42-Epi-rapamycin and pharmaceutical compositions thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Daniel Castro ; Steven Wu ; Kevin L. Woolbright ; Kurt W. Scheinpflug ; Syed F. A. Hossainy ; Li Chen, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Slepian Marvin J. (Cleveland Heights OH) Schindler Anton (Durham NC), Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein.
Solomon Donald D. (Spring Valley OH) Taller Robert A. (Centerville OH) Williamitis Victor A. (Dayton OH), Blood compatible, lubricious article and composition and method therefor.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Kao Wenling (Paoli PA) Skotnicki Jerauld S. (Allentown NJ) Abou-Gharbia Magid A. (Glen Mills PA) Palmer Yvette L. (Newtown PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapaycin.
Bacher Peter (Nurnberg DEX) Walenga Jeanine M. (Lombard IL), Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Drug delivery balloon catheter with line of weakness.
Fitzhugh,Anthony L.; Cafferata,Robert; Keefer,Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Reiley Mark A. ; Scholten Arie ; Talmadge Karen D., Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones.
Armstrong Jay J. (Bensalem PA) Sehgal Surendra N. (Princeton NJ), Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements.
Bucay-Couto, Weenna; Li, Jamie (Jianmin), Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface.
Skotnicki Jerauld S. (Allentown NJ) Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne NJ) Kearney Robert M. (Lawrenceville NJ), Macrocyclic immunomodulators.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Medical device coated with interpenetrating network of hydrogel polymers.
Rosen Gerald M. ; Herzog ; Jr. William R. ; Pou Sovitj, Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosy.
Fan You-Ling (East Brunswick NJ) Marlin Lawrence (Bridgewater NJ) Sahatjian Ronald A. (Lexington MA) Schultz Steven A. (Northboro MA), Medical device with lubricious coating.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Method for making a drug delivery balloon catheter.
Zhong Sheng-Ping (Farum DKX), Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with s.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Conway Anthony J. (Chatfield MN) Conway Philip J. (Chatfield MN) Fryar ; Jr. Richard D. (Rochester MN), Microcidal agent releasing catheter with balloon.
Roorda,Wouter E.; Ding,Ni; Pacetti,Stephen D.; Michal,Eugene T.; Shah,Ashok A.; Hossainy,Syed F. A., Polyacrylates coatings for implantable medical devices.
Failli Amedeo (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Sehgal Surendra N. (Dollard des Ormeaux CA) Blazekovic Teodora M. (Mount Royal CA) Vezina Claude (Deux-Montagnes CA), Rapamycin and process of preparation.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Kao Wenling (Paoli PA) Vogel Robert L. (Stratford NJ) Abou-Gharbia Magid A. (Glen Mills PA) Caufield Craig E. (Princeton Junction NJ), Rapamycin oximes and hydrazones.
Roorda,Wouter E.; Hossainy,Syed F. A.; Ding,Ni; Tang,Fuh Wei; Pacetti,Stephen D., Rate limiting barriers for implantable devices and methods for fabrication thereof.
Gregory T. Sydney ; Russ Seiber ; Arthur R. Madenjian ; Annette Belovi, Selective coating of a balloon catheter with lubricious material for stent deployment.
Sydney Gregory T. ; Seiber Russ ; Madenjian Arthur R. ; Belovi Annette, Selective coating of a balloon catheter with lubricious material for stent deployment.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a pol.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Nilsson Bo (Helsingborg SEX) Kalland Terje (Lddekpinge SEX) Termander Birgitta (Helsingborg SEX), Use of Linomide to increase hemopoietic cell precursors.
Ahlering, Michael Thomas; Yamamoto, Ronald Kenichi; Elicker, Robert John; Nguyen, Tien Thuy; Shulze, John Edwin; Zoethout, Jelle Jurjen, Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs.
Ahlering, Michael Thomas; Yamamoto, Ronald Kenichi; Elicker, Robert John; Nguyen, Tien Thuy; Shulze, John Edwin; Zoethout, Jelle Jurjen, Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.